secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0000950103-22-008134
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen Q1 revenue $32M (+31% YoY); Fast Track for PRGN-3006 in AML
--------------------------------------------------------------------

- Total revenues $32.0M, up 31% vs $24.5M YoY; net loss $19.3M ($0.10/share).
- Cash, equivalents, short- & long-term investments $142.1M as of March 31, 2022.
- FDA Fast Track designation for PRGN-3006 UltraCAR-T in relapsed/refractory AML.
- Phase 2 study for PRGN-2012 in RRP dosed first patient; Phase 1b expansion arm for PRGN-3006 initiated.
- R&D expenses rose $2.2M (+21%) driven by clinical/preclinical program advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322008134/0000950103-22-008134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322008134/dp172815_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-22-008134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer